Format
Sealed research vial
Trust signal
COA-backed inventory
Safety Data Sheet
Download SDS
Full safety documentation for this compound.
99%+ Purity
Lab-grade supply. Limited AU stock.
From A$64.99
Select options below
Size
Select one
Select your preferred options to continue.
Third-party tested · 99%+ purity · Dispatched within 24h from Melbourne · 4.8★ #1 on Trustpilot
Fast AU dispatch, tracked delivery, and documentation-ready inventory.
Multi-buy: any 3+ items, 15% off everything — applied automatically.
Why labs buy from APL
High purity, consistent supply, and fast AU-wide dispatch.
Certificate of Analysis
Certificate of Analysis
Verified purity: 99.546%
BPC-157
From A$64.99
BPC-157 is a 15-amino acid pentadecapeptide derived from human gastric juice protein BPC, studied in cell-migration and angiogenic-signalling assay models.
Research discussion of BPC-157 typically centres on its proposed cytoprotective and angiogenic signalling readouts in endothelial and epithelial cell models. Selectivity controls and pathway antagonists (for example NO-synthase inhibitors) are common design elements when attributing migration or tube-formation effects specifically to BPC-157.
Browse Inventory
In research literature, BPC-157 is generally treated as a 15-amino acid pentadecapeptide derived from human gastric juice protein BPC, studied in cell-migration and angiogenic-signalling assay models. BPC-157 is a 15-amino acid pentadecapeptide derived from the partial sequence of human gastric juice protein BPC. In cell-based models it has been studied for interactions with NO/eNOS signalling, VEGFR2-mediated angiogenic pathways, and focal adhesion kinase (FAK)/paxillin complexes relevant to cell-migration assays. Its small size and lack of cysteine residues make it relatively stable in handling compared with larger disulfide-containing peptides.
Research discussion of BPC-157 typically centres on its proposed cytoprotective and angiogenic signalling readouts in endothelial and epithelial cell models. Selectivity controls and pathway antagonists (for example NO-synthase inhibitors) are common design elements when attributing migration or tube-formation effects specifically to BPC-157. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether BPC-157 behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.
Potential research applications for BPC-157 should be framed strictly in analytical and laboratory terms. Typical reasons a team might review this product page include:
Handling decisions should always follow the vial label, internal SOPs, and any product-specific documentation. A conservative laboratory baseline for BPC-157 is:
A product-specific COA is linked on this page, with purity noted as 99.546%. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.
When teams compare BPC-157 with BPC-157 + TB-500, GHK-CU, and Melanotan 2, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.
Certificate of Analysis
Certificate of Analysis
Verified purity: 99.546%
It brings together 2 labelled variants: 5mg and 10mg, current pricing context, stock visibility, COA access, and internal links to related catalogue pages so a laboratory buyer can review the material from a single reference URL.
BPC-157 is generally discussed as a 15-amino acid pentadecapeptide derived from human gastric juice protein BPC, studied in cell-migration and angiogenic-signalling assay models. The most relevant background is sequence behaviour, pathway or receptor context where documented, and analytical consistency under controlled laboratory conditions.
Use the label, COA, and internal SOPs as the primary guide. In general, store the material under controlled laboratory conditions, minimise avoidable environmental exposure, and keep variant tracking records current.
Yes. This listing includes access to a product-specific COA, which should be reviewed before use so purity, identity, and documentation checks are aligned with the project record.
No. The page should be interpreted strictly in a research and laboratory context. It does not provide dosage guidance, treatment claims, or human or animal use instructions.
